Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.88 |
| ▸ | ABL1 | P00519 | 5/20 | 0.69 |
| ▸ | EGFR | P00533 | 5/20 | 0.69 |
| ▸ | ABL2 | P42684 | 5/20 | 0.69 |
| ▸ | CDK1 | P06493 | 2/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802962 | 1.00 | SRC (0.88) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7847645 | 0.93 | SRC (1.00) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL6246578 | 0.90 | SRC (0.74) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7835919 | 0.88 | SRC (0.76) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7843527 | 0.88 | SRC (0.85) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL3183902 | 0.88 | SRC (0.74) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7844022 | 0.87 | SRC (0.75) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7845672 | 0.87 | SRC (0.89) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7847655 | 0.86 | SRC (0.82) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7835317 | 0.83 | SRC (1.00) | SRCABL1EGFRABL2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240224960-A1 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | PESTELL RICHARD G (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240224960-A1 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | PESTELL RICHARD G (US) | 2024-07-11 | — | — | US | disclosed |
| US-11920164-B2 | Media for culturing naive human pluripotent stem cells | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-05 | — | — | US | disclosed |
| EP-3194572-B1 | MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | YEDA RES & DEV (IL) | 2023-10-25 | — | — | EP | disclosed |
| US-10952415-B2 | Prostate cancer cell lines, gene signatures and uses thereof | Pestell, Richard G. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20170275593-A1 | MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-09-28 | — | — | US | disclosed |
| US-9555034-B2 | Compositions and methods for treating skin cancer associated diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160235807-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | SYNERGY PHARMACEUTICALS INC. | 2016-08-18 | — | — | US | disclosed |
| US-20150335644-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN CANCER ASSOCIATED DISEASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-11-26 | — | — | US | disclosed |
| US-9101631-B2 | Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer | GEORGETOWN UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080193504-A1 | Method to Treat and Prevent Posterior Capsule Opacification | THOMAS JEFFERSON UNIVERSITY | 2008-08-14 | — | — | US | disclosed |
| EP-1893292-A2 | METHOD TO TREAT AND PREVENT POSTERIOR CAPSULE OPACIFICATION | THOMAS JEFFERSON UNIVERSITY (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007116025-A2 | USE OF C-SRC INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2006128152-A2 | METHOD TO TREAT AND PREVENT POSTERIOR CAPSULE OPACIFICATION | THOMAS JEFFERSON UNIVERSITY (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | SRC 901/4885ABL1 1691/4885EGFR 2358/4885 |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | SRC 1/4885ABL1 25/4885EGFR 124/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | SRC 1/4885ABL1 26/4885EGFR 155/4885 |
| US-10952415-B2 | Prostate cancer cell lines, gene signatures and uses thereof | MYC, MYCBP, CD44 | SRC 9/4885ABL1 1430/4885EGFR 208/4885 |
| US-20240224960-A1 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | MYC, MYCBP, CD44 | SRC 11/4885ABL1 1623/4885EGFR 249/4885 |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | SRC, CHUK, CTTN | SRC 1/4885ABL1 14/4885EGFR 233/4885 |
| US-20160235807-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | GUCY1A1, GUCY1A2, GUCY1B2 | SRC 1570/4885ABL1 3557/4885EGFR 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.